Paclitaxel-coated Balloon for Treatment of De-novo Non-complex Coronary Artery Lesions

• Status: Recruiting
• Trial end date: 2028-04-01
• Target enrollment: 0
• Participant gender: All

Summary

The introduction of Bare-metal stents (BMS) since 1986 has alleviated the limitations of plain old balloon angioplasty (POBA) related elastic recoil and flow-limiting dissections. Later on, higher restenosis rates due to exaggerated neointimal growth in BMS has led to the development of drug-eluting stents (DES), which elutes an antiproliferative drug to the vessel wall and reduce the restenosis rate. However, late stent thrombosis and restenosis, with a hazard of nearly 2% per year after implantation, remained a concern and motivated the development of drug-coated balloons (DCB).

The advantages of DCB are that leaving no metal in the blood vessel and respect the vessel anatomy.

Recently, studies with the strategy of DCB angioplasty with bailout stenting have demonstrated safety and efficacy for the small-vessel disease. In the BASKET-SMALL 2 trial, which compared SeQuent Please DCB with EES or Taxus DES in the vessels that have reference diameter<3mm, showed that at 12-month follow-up, DCB was non-inferior to DES (MACE [cardiac death, non-fatal myocardial infarction, and target-vessel revascularisation] rates: 8% vs. 9%).

Although some small-scale RCT using surrogate endpoints have reported that no significant difference in MLD or late lumen loss between the two groups in large vessels, up to now, there is no large-scale RCT comparing the clinical outcomes of DCB versus DES in large vessels with de novo lesions.

Therefore, the investigators hypothesized that in patients undergoing non-complex percutaneous coronary intervention (PCI) for de-novo stenoses, drug-coated balloon (DCB) is non-inferior to drug-eluting stents (DES).

Besides the ischemic events to be observed, there might be also a potential benefit of the DCB strategy by reducing the bleeding events. Although there is scarce evidence showing the optimal DAPT duration for DCB, in the current study, according to our empirical clinical experiences and previous expert consensus, the investigators chose aspirin + Ticagrelor/Clopidogrel for 3-month followed by Ticagrelor/Clopidogrel monotherapy for 3-month to be the antiplatelet regimen in DCB arm. In contrast to the antiplatelet regimen for the DES arm used in the current trial, which is aspirin + Ticagrelor/Clopidogrel for 3-month followed by Ticagrelor/Clopidogrel monotherapy for 9-month, the DCB and its antiplatelet strategy is estimated to reduce the bleeding events during follow-up.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Xijing Hospital
• Treatments: Aspirin; Clopidogrel; Paclitaxel; Sirolimus; Ticagrelor

Criteria

Inclusion Criteria:

1. Patients with an indication for PCI due to acute or chronic coronary syndrome

2. Patients with de-novo, non-complex lesion* and underwent successful pre-dilation**

3. Patients who are able to complete the follow-up and compliant to the prescribed medication

• Non-complex PCI is defined as

1. Vessels treated<3; stents implanted<3; lesions treated<3 or Total stent length<60 mm 2. Bifurcation does not require 2 stents 3. Non left main lesion 4. Non venous or arterial graft lesion 5. Non chronic total occlusion lesion 6. Do not require the use of atherectomy device

**Successful pre-dilation is defined as fulfilling all the following criteria

1. Thrombolysis In Myocardial Infarction [TIMI] flow =3

2. Without dissections type D, E, and F

3. Residual stenoses <30% after balloon pre-dilation (visual).

4. Without serious complication requiring the termination of PCI

Exclusion Criteria:

1. Under the age of 18

2. Unable to give informed consent

3. The patient is a woman who is pregnant or nursing (a pregnancy test must be performed within 7 days prior to the index procedure in women of child-bearing potential according to local practice)

4. Known contraindication to medications such as Heparin, antiplatelet drugs, or contrast.

5. Currently participating in another trial and not yet at its primary endpoint

6. The concurrent medical condition with a life expectancy of less than 2 years

7. Previous intracranial hemorrhage

8. In-stent stenosis requiring revascularization (defined as stenosis≥50% by visual or positive functional assessments in any vessel)

9. Atrial fibrillation

10. Prior CABG

11. Cardiogenic shock